Appointment of paul brennan as non-executive director

Melbourne, australia, march 16, 2022 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of paul brennan as an independent non-executive director of the company with effect from today.
IMRN Ratings Summary
IMRN Quant Ranking